In contrast, the recently published AMLSG-09-09 phase III trial investigated consolidation treatment with high-dose cytarabine and all-trans retinoic acid (ATRA), with or without GO in AML patients with NPM1 mutations. The gene discussed is NPM1; the disease is acute myeloid leukemia.